More information: www.emergpharma.com
- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
Pharmaceutical Emerging Markets презентация
Содержание
- 1. Pharmaceutical Emerging Markets
- 2. Global Pharmaceutical Market 2011-2013 (bn USD) +2% -1 % +10% Source: Emergpharma Pannel
- 3. Emerging Markets (bn USD) +3% +17% Source: Emergpharma Pannel
- 4. Developed Markets(bn USD) -1% +2% -7% Source: Emergpharma Pannel
- 5. Market Growth 2013 (bn USD by Segment) +25,3 +4,6 -8,1 Source: Emergpharma Pannel
- 6. Top 12 Pharma in Global Market Novartis,
- 7. Pharma Top 12 in Global, Developed and Emerging Markets Source: Emergpharma Pannel
- 8. Market Growth Drivers 2013 Source: Emergpharma Pannel
- 9. Summary Global Pharmaceutical market grew 2% in
Global Pharmaceutical Market
2011-2013 (bn USD) +2% -1 % +10% Source: Emergpharma Pannel
Слайд 1Pharmaceutical Emerging Markets
Impact on Global Pharmaceutical Market 2012-2013
Emergpharma Pannel Preliminary
Results
Слайд 6Top 12 Pharma in Global Market
Novartis, Pfizer, Merck, Sanofi, GSK, Roche,
Astra, J&J, Abbvie, Teva, Lilly and Boehringer Ingelheim
+3%
-1%
Source: Emergpharma Pannel
Слайд 9Summary
Global Pharmaceutical market grew 2% in 2013 although Developed and Emerging
Markets played a very different role
While EM delivered 30 bn USD of additional revenues, DM reduced sales more than 8 bn USD
Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while USA, Canada, Japan and other APAC developed markets grew at an average of 2%
In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion
Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%)
In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%)
While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment
While EM delivered 30 bn USD of additional revenues, DM reduced sales more than 8 bn USD
Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while USA, Canada, Japan and other APAC developed markets grew at an average of 2%
In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion
Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%)
In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%)
While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment
Source: Emergpharma Pannel
